Solésence reported Q4 2025 revenue of $12.5 million, essentially flat year over year, with net income turning modestly positive as margins improved, while full year 2025 revenue reached a record $62.1 million but profitability declined versus 2024; after-hours movement was not disclosed in the release.
About Solésence
Solésence, Inc. (Nasdaq ticker SLSN) is a beauty and life sciences company that develops mineral-based sun care and skin health solutions for brand partners worldwide. Headquartered in Romeoville, Illinois, Solésence focuses on innovative formulations that integrate protection, prevention and treatment technologies into daily-use skin care, sun care and color cosmetic products.
The company delivered record 2025 revenue of $62.1 million, implying a small-cap market capitalization in the tens of millions of dollars, consistent with recent trading prices below $1.10 per share. Founded as part of a broader materials and health-science platform, Solésence positions itself as a partner-of-choice for brands seeking advanced mineral protection technologies. Recent disclosures show a 2025 P/E ratio above 60 at a market cap near $63 million, reflecting modest net income and high growth expectations.
Top Financial Highlights
- Q4 2025 net revenue was $12.5 million, roughly flat versus $12.6 million in Q4 2024.
- Full year 2025 revenue reached a record $62.1 million, up 19% from 2024.
- Full year 2025 net income was $1.8 million, down from $4.2 million in 2024.
- Q4 2025 gross profit was about $3.4 million, with gross margin improving to 27% from 22% in Q4 2024.
- Full year 2025 gross margin declined to 26% from 31% in 2024 as cost pressures offset volume growth.
- Q4 2025 net income was approximately $0.2 million, marking a return to profitability after a Q3 net loss of $1.1 million.
- Q3 2025 revenue had fallen to $14.5 million, down 14% year over year, highlighting the recovery in Q4 margin but softer top-line growth.
- Adjusted EBITDA for the nine months ended September 30, 2025 was $3.3 million, compared with $6.5 million in the prior-year period, signaling lower operating leverage.
- Operating expenses for the nine months ended September 30, 2025 rose to about $11.2 million, up from $8.1 million a year earlier, driven by higher SG&A and R&D.
- Cash on hand as of September 30, 2025 was approximately $0.4 million, down from $1.4 million at December 31, 2024, offset by increased use of related-party credit lines.
- Trade accounts receivable net rose to about $9.7 million at September 30, 2025, from $4.9 million at year-end 2024, reflecting higher customer balances and expanded sales.
- Inventories declined slightly to about $18.9 million at September 30, 2025, from $20.3 million at December 31, 2024, as the company rationalized production.
- Management highlighted the addition of roughly 20 new brand partners in 2025 and targeted further growth in 2026 through expanded consumer product lines.
- The company did not provide detailed numerical quarterly EPS in the accessible summaries but indicated diluted EPS compression for 2025 versus 2024.
- 2026 guidance referenced continued revenue growth with a focus on margin improvement, though specific dollar targets were not detailed in secondary summaries.
Beat or Miss?
| Metric | Reported | Difference/Analysis |
| Q4 2025 Revenue | $12.5 million | Roughly flat vs. $12.6 million prior year, no explicit consensus given so comparison to expectations is N/A. |
| FY 2025 Revenue | $62.1 million | Up 19% year over year, described as record revenue, but narrative suggests margin pressure limited earnings leverage. |
| FY 2025 Net Income | $1.8 million | Down from $4.2 million in 2024, reflecting weaker profitability despite higher sales; no explicit analyst estimate cited. |
| Q4 2025 Gross Margin | 27% | Improved from 22% in Q4 2024, signaling early impact of operational changes, with no direct consensus benchmark provided. |
| FY 2025 Gross Margin | 26% | Down from 31% in 2024 due to cost and mix dynamics, implying a miss on internal margin ambitions rather than stated Street estimates. |
What Leadership Is Saying?
“As part of our ongoing transformation, Solésence implemented several strategic initiatives driving improvements in innovation, product quality and operational efficiency, and we are confident that our wider organizational and commercial strategies will solidify Solésence’s future as a dynamic, highly profitable growth company.”
“Our recent structural changes focused on streamlining operations, enhancing product integrity, and improving productivity have strategically positioned Solésence for scaled growth, providing the sound operational foundation necessary to efficiently deliver the highest quality products to our brand partners.”
Historical Performance
| Category | Q4 2025 (or FY 2025) | Q4 2024 (or FY 2024) | Change (%) |
| Revenue | $12.5 million Q4 2025 / $62.1 million FY 2025 | $12.6 million Q4 2024 / about $52.2 million FY 2024 (implied) | Q4 roughly flat, full year up about 19%. |
| Net Income | About $0.2 million Q4 2025, $1.8 million FY 2025 | Net income higher in 2024 at about $4.2 million FY 2024 | Profitability down by more than 50% year over year despite revenue growth. |
| Operating Expenses | About $11.2 million for first nine months 2025 | About $8.1 million for first nine months 2024 | Operating expenses up roughly 38%, pressuring margins and net income. |
| Category | Q4 2025 vs Q4 2024 – Peers | Q4 2024 vs Q4 2023 – Peers | Change (%) |
| Revenue | Limited direct peer data available for the same period so comparable competitor revenue change is not disclosed. | N/A | N/A due to lack of consistent public competitor quarterly breakdowns in accessible sources. |
| Net Income | Peer net income data for direct mineral-based sun care specialists is not consistently reported at the same granularity. | N/A | N/A as public filings of competitors are not aligned to Solésence’s specific reporting segments. |
| Operating Expenses | Public competitor disclosures do not provide directly comparable operating expense lines for this niche segment for Q4 2025. | N/A | N/A because of inconsistent reporting taxonomies across peers. |
How the Market Reacted?
Recent trading shows Solésence shares around 0.90-1.10 dollars with a market cap near 63 million dollars, but immediate post-release price reaction for the Q4 2025 report was not clearly detailed in secondary sources. Earlier in 2025 the stock had dropped sharply after a weak Q3 report, which likely influenced investor caution going into the Q4 release. The latest Q4 and full-year 2025 update mixes record revenue with weaker full-year profitability but improving Q4 margin, which points to a cautious but improving sentiment rather than a clearly bullish or bearish reaction.
